Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective

References

• National Health Service. Symptoms: atopic eczema. 2019 Dec 5 [Internet]; [cited 2022 Nov 22]. Available at https://www.nhs.uk/conditions/atopic-eczema/symptoms/.
   Google Scholar
• Katoh N, Ohya Y, Ikeda M, et al. Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, the Japanese Society of Allergology, the Japanese Dermatology Association. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69(3):356–369. doi: 10.1016/j.alit.2020.02.006.
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: 10.1016/S0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatol. 2017;153(5):406–412. doi: 10.1001/jamadermatol.2016.5538.
   PubMed Web of Science ®Google Scholar
• Costanzo A, Amerio P, Asero R, et al. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Ital J Dermatol Venerol. 2022;157(1):1–12. doi: 10.23736/S2784-8671.21.07129-2.
   Google Scholar
• Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381–388.e2. doi: 10.1016/j.anai.2019.07.008.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Single technology appraisal. Dupilumab for treating moderate to severe atopic dermatitis after topical treatments [ID1048] [Internet]; [cited 2022 Nov 22]. Committee Papers. Available at https://www.nice.org.uk/guidance/ta534/documents/committee-papers. Accessed 22 November 2022.
   Google Scholar
• Sciattella P, Pellacani G, Pigatto PD, et al. The burden of atopic dermatitis in adults in Italy. G Ital Dermatol Venereol. 2020;155(1):19–23. doi: 10.23736/S0392-0488.19.06430-7.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Rind D, Chapman R, et al. Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol. 2018;17(7):750–756.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: 10.1111/jdv.18429.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Dupixent: authorisation details. 2017 Sep 26 [Last update: 2021 Jan 22; cited 2022 Nov 22]. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent#authorisation-details-section.
   Google Scholar
• European Medicines Agency. Protopic: authorisation Details. 2002 Feb 27 [Last update: 2020 Sep 7; cited 2022 Nov 22]. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/protopic#authorisation-details-section.
   Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020.
   PubMed Web of Science ®Google Scholar
• Aldredge LM, Young MS. Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biologic therapy: role of the nurse practitioner and physician assistant. J Dermatol Nurses Assoc. 2016;8(1):14–26. doi: 10.1097/JDN.0000000000000185.
   PubMedGoogle Scholar
• Ariëns LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116–126. doi: 10.1111/all.14080.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Olumiant: authorisation Details. 2017 Feb 13 [Last update: 2020 Dec 15; cited 2022 Nov 22]. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant#authorisation-details-section.
   Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298–5307. doi: 10.4049/jimmunol.0902819.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour J-P, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343. doi: 10.1001/jamadermatol.2020.3260.
   PubMed Web of Science ®Google Scholar
• Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance, or contraindication to cyclosporine: results from a randomized, placebo-controlled, phase iii clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338–352. doi: 10.1111/bjd.21630.
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency (AIFA). DUPIXENT (dupilumab) dermatite atopica (AD). 2022. [Internet]; [cited 2022 Nov 22]. Available at https://www.aifa.gov.it/documents/20142/1663139/Scheda_Registro_DUPIXENT_08.03.2022.zip.
   Google Scholar
• Italian Medicines Agency (AIFA). Guidelines for the compilation of the dossier to support the reimbursability and price application of a medicine. Version 1, 2020. [Internet]; [cited 2022 Nov 22] Available at https://www.aifa.gov.it/documents/20142/1283800/Linee_guida_dossier_domanda_rimborsabilita.pdf.
   Google Scholar
• Eli Lilly and Company Limited. Olumiant (baricitinib) 4 mg film-coated tablets. Summary of product characteristics. [Internet]; [cited 2022 Nov 22] Available at https://www.medicines.org.uk/emc/product/7486/smpc#.
   Google Scholar
• Sanofi Genzyme. Dupixent (dupilumab) 300 mg solution for injection in pre-filled pen. Summary of product characteristics. [Internet]; [cited 2022 Nov 22]. Available at https://www.medicines.org.uk/emc/product/11321/smpc.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Dupilumab for treating moderate to severe atopic dermatitis after topical treatments. Technology appraisal guidance [TA534]. 1 August 2018. [Internet]; [cited 2022 Nov 22]. Available at https://www.nice.org.uk/guidance/ta534.
   Google Scholar
• Papadia DG, FARMACOECONOMIA e FARMACOEPIDEMIOLOGIA. Università degli Studi di Trieste – Corsi di Studio in Farmacia Per gli studenti del Corso di Laurea in Farmacia ed in C.T.F. – versione aggiornata marzo 2018. [Internet]; [cited 2022 Nov 22]. Available at https://moodle2.units.it/pluginfile.php/194171/mod_resource/content/1/farmeconepid.pdf. [Italian]
   Google Scholar
• de Bruin-Weller MS, Serra-Baldrich E, Barbarot S, et al. Indirect treatment comparison of baricitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(6):1481–1491. doi: 10.1007/s13555-022-00734-w.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691. doi: 10.1016/s0895-4356(97)00049-8.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant tropical corticosteroid treatment in adults with atopic dermatitis with an inadequate response to intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. doi: 10.1111/bjd.16156.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40–45. doi: 10.1016/j.anai.2020.07.026.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226–232. doi: 10.1016/j.jaci.2006.02.031.
   PubMed Web of Science ®Google Scholar
• I.Stat. Life tables. 2019. [Internet]; [cited 2022 Nov 22]. Available at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_MORTALITA1#.
   Google Scholar
• van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715. doi: 10.1016/j.jval.2012.02.008.
   PubMed Web of Science ®Google Scholar
• Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value Health. 2013;16(5):814–822. doi: 10.1016/j.jval.2013.04.008.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539–545. doi: 10.1016/j.jval.2010.10.029.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bégo-Le-Bagousse G, Eckert L, et al. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther (Heidelb). 2017;7(4):493–505. doi: 10.1007/s13555-017-0201-6.
   PubMed Web of Science ®Google Scholar
• Compendio Farmadati. 2020. [Internet]; [cited 2022 Nov 22]. Available at https://www.farmadati.it/. [Italian]
   Google Scholar
• Information Hospital Service. 2021. [Internet]; [cited 2022 Nov 22]. Available at https://www.infohospital.com/en/index.html.
   Google Scholar
• Gelmetti C, Girolomoni G, Patrizi A. revisione critica di linee guida e raccomandazioni pratiche per la gestione dei pazienti con dermatite atopica. [Internet]; [cited 2022 Nov 19]. Available at https://www.pacinimedicina.it/wp-content/uploads/dermatite-atopica_sidemast.pdf. [Italian]
   Google Scholar
• Gazzetta Ufficiale. 2013. 23. [Italian]
   Google Scholar
• Garattini L, Castelnuovo E, Lanzeni D, et al. Durata e costo delle visite in medicina generale: il progretto DYSCO. FE. 2003;4(2):109–114. [Italian] doi: 10.7175/fe.v4i2.773.
   Google Scholar
• Ministry of Health. Pronto Soccorso e sistema 118 - Proposta metodologica per la valutazione dei costi dell’emergenza. 2021. [Italian]
   Google Scholar
• Nomenclatore Tariffario FASDAC. 2020.
   Google Scholar
• Sistema Socio Sanitario. Regione Lombardia ASST Spedali Civili. Psicologia. 2022. [Internet]; [cited 2022 Dec 8]. Available at https://www.asst-spedalicivili.it/servizi/Menu/dinamica.aspx?idSezione=616&idArea=38147&idCat=40274&ID=45520&TipoElemento=categoria. [Italian]
   Google Scholar
• Palmonella A. Gli psicologi penitenziari chiedono aiuto all’ordine degli psicologi. [Internet]; [cited 2022 Dec 8]. Available at https://www.altrapsicologia.it/articoli/gli-psicologi-penitenziari-chiedono-aiuto-allordine-degli-psicologi-2/?print=print. [Italian]
   Google Scholar
• Tariffario FISDAF. 2016. [Italian]
   Google Scholar
• Tariffario regionale per la remunerazione delle prestazioni di assistenza ospedaliera. 2017. [Internet]; [cited 2022 Dec 8]. Available at https://www.regione.sardegna.it/documenti/1_26_20171122122049.pdf. [Italian]
   Google Scholar
• Decreto Commissario ad acta U00310/13. Approvazione del tariffario regionale per la remunerazione delle prestazioni di assistenza ospedaliera D.M.18.10.12. [Internet]; [cited 2022 Nov 22]. Available at https://www.asl.vt.it/Staff/SistemiInformativi/Documentazione/sio/pdf/Decr_U00310_04_07_2013.pdf. [Italian]
   Google Scholar
• Institute for Clinical and Economic Review (ICER). Dupilumab and crisaborole for atopic dermatitis: effectiveness and value final evidence report and meeting summary. 8 June 2017. [Internet]; [cited 2022 Nov 22]. Available at https://icer.org/wp-content/uploads/2020/10/MWCEPAC_ATOPIC_FINAL_EVIDENCE_REPORT_060717.pdf.
   Google Scholar
• Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691–699. doi: 10.1001/jamadermatol.2021.1273.
   PubMed Web of Science ®Google Scholar
• Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi: 10.1016/j.jaad.2019.07.074.
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1–233. i-iv. doi: 10.3310/hta10460.
   PubMed Web of Science ®Google Scholar
• Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801–807. doi: 10.1111/j.1365-2133.2008.08436.x.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Adtralza (tralokinumab): authorisation details. 2021 Jun 17. [Internet]; [cited 2022 Nov 22]. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza#authorisation-details-section.
   Google Scholar
• European Medicines Agency. Cibinqo (abrocitinib): authorisation details. 2022 Oct 11. [Internet]; [cited 2022 Nov 22]. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo#authorisation-details-section.
   Google Scholar
• European Medicines Agency. Rinvoq (upadacitinib): authorisation details. 2022 Sep 22. [Internet]; [cited 2022 Nov 22]. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq#authorisation-details-section.
   Google Scholar